摘要
目的:观察方舱3号方配合八段锦对方舱医院2019冠状病毒病(COVID-19)轻型和普通型患者的临床疗效影响。方法:选取方舱医院收治的113例COVID-19轻型和普通型患者为研究对象,采用方舱3号方内服配合八段锦治疗,回顾性分析年龄、性别、临床表现、临床疗效及胸部CT、新型冠状病毒核酸检测转阴信息及转归情况。结果:113例患者中女性112例,男性1例,平均年龄(46.66±12.91)岁。临床表现以发热、咳嗽、胸闷、纳差、乏力、腹泻为主,治疗有效率93.14%(95/102),0例转重症。CT结果多显示吸收期改变,有效率86.87%(86/99)。新型冠状病毒核酸检测转阴时间平均为8.1d。治愈出院97例,转定点医院16例,平均住院时间(16.83±5.69)d。结论:方舱3号方配合八段锦对轻型和普通型COVID-19有很好的临床疗效,能减轻患者症状,预防病情加重,缓解患者心理压力。
Objective:To observe the clinical effects of Fangcang No.3 Formula combined with Baduanjin on patients with light and common Corona Virus Disease(COVID-19)in Fangcang hospital.Methods:A total of 113 patients with light and common COVID-19 from Fangcang hospital were selected and treated with Fangcang No.3 Formula combined with Baduanjin.Finally,the age,gender,clinical manifestations,clinical efficacy,chest CT,nucleic acid detection negative conversion rate and cure rate were retrospectively analyzed.Results:Among the 113 patients,112 were female and 1 was male,with an average age of(46.66±12.91)year old.The clinical manifestations were mainly fever,cough,chest tightness,anorexia,fatigue,and diarrhea.The treatment efficiency was 93.14%(95/102),and 0 case were severe.CT imaging often showed changes in the absorption period,and the efficiency was 86.87%(86/99).The average time for viral nucleic acid detection to turn negative was 8.1 d.Finally,97 cases were cured,16 cases were transferred to designated hospitals,and the average length of stay was(16.83±5.69)d.Conclusion:Fangcang No.3 Formula combined with Baduanjin has a good clinical effect on light and common COVID-19,which could relieve the patient’s symptoms,prevent the disease from aggravating,and relieve the patient’s psychological pressure.
作者
叶舒婷
戴飞跃
胡华
徐寅
盛望
李妲
李菁
王军
彭杰
孙爽
林泉成
胡哲
龚后武
朱镇华
朱莹
YE Shu-ting;DAI Fei-yue;HU Hua;XU Yin;SHENG Wang;LI Da;LI Jing;WANG Jun;PENG Jie;SUN Shuang;LIN Quan-cheng;HU Zhe;GONG Hou-wu;ZHU Zhen-hua;ZHU Ying(The First Hospitol of Hunan University of Chinese Medicine,Changsha 410200,China;DHC Mediway Technology Co.,Ltd.,Changsha 410200,China)
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2020年第7期3742-3745,共4页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
湖南省中医药防治新冠肺炎科研攻关项目(No.KYGG02)
关键词
2019冠状病毒病
方舱3号方
八段锦
方舱医院
新型冠状病毒肺炎
瘟疫
传染病
Corona Virus Disease 2019(COVID-19)
Fangcang No.3 Formula
Baduanjin
Fangcang hospital
Novel Coronavirus Pneumonia(NCP)
Plague
Infectious disease